XNCR News and Press, Xencor Inc. From 12/17/25

2025-12-17 11:52:55 ET More on Incyte, Xencor Tracking Baker Brothers Portfolio - Q3 2025 Update Incyte Corporation (INCY) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow Incyte Corporation (INCY) Discusses mutCALR Data and Therap...

2025-12-17 06:15:16 ET Barclays analyst issues OVERWEIGHT recommendation for XNCR on December 17, 2025 10:59AM ET. The previous analyst recommendation was Overweight. XNCR was trading at $16.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100 million to $120 million in potential royalty revenue estimated to be received by Xencor, based on consensus sales forecasts -- ...

2025-11-05 17:37:23 ET More on Xencor Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release Xencor slides amid plan...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates. ...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

2025-10-29 05:22:45 ET Etzer Darout from Barclays issued a price target of $23.00 for XNCR on 2025-10-29 08:37:10. The adjusted price target was set to $23.00. At the time of the announcement, XNCR was trading at $14.25. The overall price target consensus is at $16.67 wi...

2025-10-24 17:37:40 ET Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma October 24, 2025 1:30 PM EDT... Read the full article on Seeking Alpha For further details see: Xencor, Inc. (XNCR) Discusses ...

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- --...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Ph...